80 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
, to be presented at the American Society of Gene & Cell Therapy (ASGCT), in a poster presentation that will be available on the conference’s website May 11 at 8:00 … ) for people with synovial sarcoma and MRCLS at the American Society of Clinical Oncology (ASCO) on June 4th during the Sarcoma Session starting at 1:30 p.m
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma
June: preliminary data at American Society of Clinical Oncology (ASCO)
November: full … update at Connective Tissue Oncology Society (CTOS)
SURPASS Phase 1 trial with ADP-A2M4CD8 (next-generation product targeting MAGE-A4)
September
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
29 Apr 20
Other Events
8:06am
).
Upcoming Congress Presentations
American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
A poster presentation entitled “Driving ADP-A2M4 SPEAR …
American Society of Clinical Oncology (ASCO) Annual Meeting
An oral presentation entitled “Phase 1 Dose Escalation and Expansion Trial to Assess Safety
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
and corporate events
Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting (November 10-13)
Abstract Title: SPEARHEAD-1: A Phase 2 trial … a.m. EST on November 11th
Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-14); Walter E. Washington Convention Center
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
.”
PRESENTATIONS AT MAJOR MEDICAL AND SCIENTIFIC MEETINGS
ADP-A2M4 data at American Society of Clinical Oncology (ASCO) Annual Meeting
An oral … the ILC 2020 from April 15-19 to August 25-28, 2020
Allogeneic platform update at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
8-K
EX-99.1
hfded01au45xuavyry0
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
r2drd 6ic
22 Oct 18
Other Events
8:38am
8-K
jp7p2 ey5o5vx219
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
pe7y3sd1im guspu
2 May 19
Other Events
7:10am
8-K
e3m l2774yq
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
vxzhms
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
otyig7f
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
b1gus
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
5s92ty3nn nmlj7
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
kx9k6dh
13 Sep 21
Other Events
7:08am
8-K
vms wicjyl
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
8s01wv5axp5
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
qo31r7kkbqym
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
i7p8xjnkkbwnobro
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
a6h5du oyv3ht2a7o27
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am